Abstract: PD47-03
Sources of Funding: none

Introduction

A family history (FH) of prostate cancer (CaP) is associated with an increased risk of CaP. However, it remains unclear how this association impacts the need for screening. The aim of this study is to evaluate the impact of FH of the diagnosis of clinically significant CaP in a large national cohort.

Methods

The study included 73,045 men from the control and screening arms of the Prostate Lung Colorectal and Ovarian (PLCO) trial, which had complete information regarding FH and CaP diagnosis. Incidence of clinically significant cancer (CS; intermediate or high risk disease) was compared by FH. The relationship between number of relatives diagnosed and age at CaP diagnosis was evaluated. Multivariable logistic regression was used to estimate odds rato (OR) and 95% confidence intervals (CI). _x000D_

Results

FH was associated with a significantly increased risk of both CaP [OR 1.6, (95% CI 1.5-1.8)] and CS-CaP [OR 1.7 (95% CI 1.5-1.8), respectively]. Furthermore, the impact of FH on CS-CaP increased with the number of family members with CaP; for participants with one relative, the OR was 1.6 (95% CI 1.5-1.8); for those with multiple relatives, the OR increased to 2.2 (95% CI 1.6-3.2). Men with younger relatives with prostate cancer (< 65 vs ≥65 years) were more likely to be diagnosed with CS-CaP, [OR 1.6, (95%CI 1.3-2.0)]. FH, number of affected relatives and age of relatives remained significant on multivariable analysis controlling for ages, race, smoking history, history of BPH, marital status employment status and study arm.

Conclusions

Detailed FH, including the number of relatives and relatives&[prime] age of at diagnosis significantly affect a man&[prime]s risk of CS-CaP and should be taken into consideration during individualized counseling about the frequency and intensity of screening.

Funding

none